Clinical Trial Update: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS [Phase 4]

View source ↗

Summary

Phase 4 evaluation of autonomic nervous system effects during the first dose of 0.5 mg fingolimod (Gilenya) in relapsing-remitting multiple sclerosis; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Nervous System Dysfunction
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod (Gilenya) (fingolimod)

Snippet

Sponsor: Jochen Vehoff | Conditions: Multiple Sclerosis, Autonomic Nervous System Dysfunction | Phase 4 | Status: COMPLETED | Results posted: 2016-04-29